Gaurav D. Shah, M.D.

Gaurav D. Shah, M.D.

Chief Executive OfficeratRocket Pharmaceuticals· In proxies 2021–2025

Pay in FY2025-49% from the year before · Rocket Pharmaceuticals stock -72.1% the same year

Gaurav D. Shah, M.D. was paid $3.5M in FY2025 (Dec), down 49%. Rocket Pharmaceuticals stock fell 72.1% that year.

Pay$100 in the stock at the end of FY20 → $6
Pay is from the Summary Compensation Table of each Rocket Pharmaceuticals proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Rocket PharmaceuticalsPublic company · 5 yr
    • Chief Executive Officer2021 – Present · 5 yrStock in role -95%
  2. Talaris Therapeutics, Inc.Public company
    • Director? – PresentNo stock prices for these years

Roles come from the proxy statements of each company.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?